βParahexyl was occasionally used as an anxiolytic in the mid-20th century, the dosage ranging from 5 mg to 90 mg.β
Read More
In this work we report a new series of phytocannabinoids that fills the gap between the pentyl and heptyl homologs of CBD and Ξ9-THC, bearing a n-hexyl side chain on the resorcinyl moiety that we named cannabidihexol (CBDH) and Ξ9-tetrahydrocannabihexol (Ξ9-THCH), respectively.
Read More
Moreover, a new series of phytocannabinoids has been reported by Linciano et al. (2020b), which fill the gap between the pentyl and heptyl homologues of CBD and Ξ9-THC, through bearing a n-hexyl side chain on the resorcinyl moiety, namely cannabidihexol (CBDH) and Ξ9-tetrahydrocannabihexol (Ξ9-THCH). Further studies currently underway to clarify the mechanism of action of these newly discovered phytocannabinoids are essential to assess their pharmacological potential. However, it can be assumed that the broad spectrum of phytocannabinoids has not yet been fully exploited.
Read More
Since the last review of phytocannabinoids (ACMD, 2016) two further analogues substituted at the 3-position of trans-(-)-β9-THC with slightly more extended alkyl chains have been described (tetrahydrocannabiphorol [THCP, 3-heptyl] (Citti, et al., 2019) and tetrahydrocannabihexol [THCH, 3-hexyl] (Linciano, et al., 2019). Their psychoactivity in humans has not been reported, although structure-activity considerations suggest that they are likely to have activity as CB 1 agonists. The fact that they have only recently been identified may be taken as an indication of their low abundance.
Read More